With its domination of the indication- and brand-specific analyses, it should come as no surprise that AstraZeneca led the ...

While Imfinzi showed some benefit in specific subgroups, it did not significantly improve overall disease-free survival for patients with NSCLC. The study found that patients with higher levels of ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor’s immune-evading ...

Imfinzi Improves Outcomes Mooradian and colleagues analyzed data from patients with unresectable stage 3 NSCLC who were treated with chemoradiotherapy: 332 received Imfinzi after chemoradiotherapy, ...

Using Imfinzi before and after surgery pared down the risk of disease recurrence, progression or death by 32% in patients with resectable stage 2 to 3b NSCLC, according to the AEGEAN data ...

IMFINZI ® (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 and CD80 proteins, countering the tumor's immune-evading ...

AstraZeneca's ADJUVANT BR.31 Phase 3 trial reveals Imfinzi didn't meet the primary endpoint for disease-free survival in early-stage NSCLC. Despite this, Imfinzi's safety profile remains consistent.

A phase 3 trial studying durvalumab (Imfinzi) among patients with stage III unresectable non­—small cell lung cancer (NSCLC) who did not have disease progression after concurrent ...

AstraZeneca (NASDAQ:AZN) said Imfinzi plus Lynparza and Imfinzi alone both significantly improved progression-free survival (PFS) in advanced endometrial cancer when added to chemotherapy in a ...

Imfinzi, when combined with chemotherapy, resulted in a median 13 months survival in a late-stage small cell lung cancer trial, the British drugmaker said on Monday, adding trial details to a ...

While the company said the data for Imfinzi monotherapy warranted further subgroup analysis, the results of MYSTIC greatly diminish the potential for Imfinzi to compete against the only checkpoint ...